Exploring New Strategies for Optimizing Bioavailability of Current and Future Drug Products
Perhaps the most critical research agenda for today’s pharmaceutical industry is achieving solubility and bioavailability of poorly soluble drug candidates. The challenges are not going away, and neither are your organization’s demands. Pharma Ed’s Solubility & Bioavailability Summit focuses on the innovative science required to overcome bioavailability/solubility challenges for API’s in a wide range of pre-clinical, clinical, and manufacturing contexts.
Featuring Representation From:
- Bayer
- Bristol-Myers Squibb
- AbbVie
- Novartis
- Ipsen BioScience
- Astra Zeneca
- Merck
- Capsugel
- Quotient Clinical
- Kashiv Pharma
- Pion
- Sirius Analytical
- H. Lundbeck
- NIST
- University of Limerick
- Gattefossé
- Center for Pharmaceutical Physics
- Agere
- University of the Sciences in Philadelphia
Featuring Comprehensive Coverage On:
- Optimizing Formulations for New Drug Product Development
- Peptide Formulation Challenges and Beyond
- De-risking New Chemical Entities for Food- and pH-Sensitivity in Early Clinical Development
- Key Formulation Considerations for Suspensions of Amorphous Dispersions
- Studying the Interplay of Dissolution, Solubility and Permeability in Formulation Development
- Re-conceptualizing Solubility & Bioavailability for Today’s API Challenges
- Using Ion Pair Formation to Enhance Solubility
- Unique Properties of Lipid-Based Formulations & Keys of Design and Testing
- Surface-facilitated Polymorphic Transformation (SurFPT)
- Spray-dried Technologies for Amorphous Stabilization of Poorly Soluble Compounds
- Fresh Research on Co-Crystals and their Impact on Bioavailability
- And Much More!
Reviews
There are no reviews yet.